What Blackstone Life Sciences does

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment business of Blackstone Inc. (NYSE: BX), focused on providing non-dilutive capital and development partnerships to pharmaceutical, biotechnology, and medical technology companies. The division was effectively created in December 2018 when Blackstone acquired Clarus, a healthcare-focused venture firm co-founded in 2005 by Dr. Nicholas Galakatos, who continues to lead BXLS as Global Head of Life Sciences and Chairman of its Investment Committees, alongside Senior Managing Director Ari Brettman, MD. BXLS operates from Cambridge, Massachusetts, with senior leadership co-located at Blackstone's New York headquarters at 601 Lexington Avenue, and serves a global enterprise client base spanning North America, Europe, the Middle East, and Asia.

BXLS delivers a modular platform of complementary financing instruments rather than a single product. Its core offering is the Blackstone Life Sciences VI fund (BXLS VI), which reached a final close at a record $6.3 billion hard cap in March 2026 — nearly 40% larger than its predecessor vehicle and the largest dedicated life sciences private fund ever raised. Around this fund vehicle, BXLS structures (i) Strategic Growth Capital Agreements — multi-year, milestone-tied funding deals exemplified by the $400 million Teva duvakitug agreement and the $700 million Merck sac-TMT R&D funding; (ii) Co-Funding Agreements for clinical development, including the Johnson & Johnson bleximenib partnership covering Phase 1–3 trials; (iii) structured Life Sciences Term Loans and Credit Facilities, such as the $570 million Axsome Therapeutics facility and the $100 million GeneDx term loan; (iv) Royalty Interest Investments, including the prior 50% LEQVIO royalty interest and the 1% AMVUTTRA interest subsequently sold to Royalty Pharma; and (v) a Company-Building / Ownership Strategy exemplified by the acquisition and build-out of Anthos Therapeutics around the abelacimab stroke-prevention therapy originally deprioritized at Novartis. Notably, BXLS-backed assets reportedly achieve an 85–86% Phase III approval success rate versus an industry average of approximately 48%.

The business model monetizes across multiple streams: (a) fund management fees and carried interest on the BXLS VI fund and prior vehicles, which collectively represent approximately $15 billion of platform assets; (b) milestone and royalty payments tied to regulatory and commercial outcomes on strategic growth capital and co-funding deals; (c) interest income and equity participation from term loan and credit facilities originated alongside Blackstone Credit & Insurance; and (d) gains from royalty monetization exits (e.g., the $310 million AMVUTTRA royalty sale) and portfolio company divestitures (e.g., the up to $3.1 billion Novartis acquisition of Anthos, with $925 million paid upfront). The customer base is overwhelmingly enterprise — large-cap pharma (Merck, Teva, J&J, Novartis, Alnylam) and mid-market biotech (Axsome, GeneDx) — accessed exclusively through senior, relationship-led direct engagement with C-suite and senior R&D / business development executives.

Name

Blackstone Life Sciences

Legal name

Blackstone Inc.

Website

https://blackstone.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment arm of Blackstone Inc., providing non-dilutive financing — strategic growth capital, royalty investments, term loans, and co-funding partnerships — to pharmaceutical and biotechnology companies developing late-stage therapeutics, backed by a record $6.3 billion flagship fund.

Ownership category

akta.pro rank

Product category

Life Sciences Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Treasury, Cash Management & Liquidity (SME) (FSAGAJAG)

Keywords

• Life sciences investment
• Biotech private equity
• Pharmaceutical R&D financing
• Royalty monetization
• Clinical development funding

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Royalty Monetization: Generates revenue by acquiring royalty interests in approved or late-stage therapeutics (e.g., a 1% royalty interest in Alnylam's AMVUTTRA, sold to Royalty Pharma for $310 million) and monetizing them through sales to royalty buyers or capturing royalty streams over time.
2. Strategic Growth Capital with Milestones and Royalties: Provides multi-year strategic growth capital to pharma partners (e.g., $400M over four years to Teva for duvakitug; $700M to Merck for sac-TMT) in exchange for regulatory/commercial milestone payments and low single-digit royalties on worldwide sales.
3. Structured Credit and Term Loans: Originates and provides term loans, revolving credit facilities, and structured credit to life sciences companies (e.g., $570M facility to Axsome Therapeutics with Blackstone Credit & Insurance; $100M term loan to GeneDx) earning interest income and equity participation.
4. Fund Management and Investment Returns: Raises dedicated life sciences private funds (BXLS VI at $6.3 billion) and deploys capital across new ventures and partnerships, generating carried interest, management fees, and investment returns on deployed capital.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Core offering

Blackstone Life Sciences (BXLS) is the dedicated life sciences investment arm of Blackstone Inc., deploying capital through its BXLS VI fund ($6.3 billion) and complementary financing instruments — including strategic growth capital, co-funding of clinical trials, structured term loans and credit facilities, and royalty interest investments — to pharmaceutical, biotechnology, and medtech companies. It also pursues a company-building strategy by acquiring and developing companies around deprioritized drug assets. The platform pairs Blackstone's scale capital with deep scientific and clinical domain expertise, evidenced by an 85–86% Phase III approval success rate on BXLS-backed assets versus a ~48% industry average.

Product overview

Blackstone Life Sciences (BXLS) is not a software product but a single operating business unit of Blackstone that delivers a platform of complementary life sciences investment vehicles rather than one unified product. Its core offering is the Blackstone Life Sciences VI fund (BXLS VI, $6.3B), which sits alongside a set of modular financing instruments: Strategic Growth Capital Agreements (e.g., the $400M Teva duvakitug deal and the $700M Merck sac-TMT R&D funding), Co-Funding Agreements (e.g., the Johnson & Johnson bleximenib partnership), Life Sciences Term Loan and Credit Facilities (e.g., the $100M GeneDx term loan and the $570M Axsome facility), Royalty Interest Investments (e.g., the AMVUTTRA and LEQVIO royalty positions), and a Company-Building / Ownership Strategy exemplified by Anthos Therapeutics. These modules fit together as a continuum of non-dilutive financing spanning early clinical co-funding, late-stage development capital, structured debt, and post-approval royalty monetization.

Differentiator

Problem solved

Functional benefit

Products and services

• Blackstone Life Sciences VI (BXLS VI) Fund Flagship dedicated life sciences private fund; raised $6.3B in capital commitments and committed nearly $2B in new investments over the prior 12 months with an 86% Phase III approval success rate. Capital is deployed across new ventures, partnerships, and biopharma/medtech financings through multiple instruments.
• Strategic Growth Capital Agreements Non-dilutive funding vehicles that BXLS deploys with pharmaceutical partners to share late-stage clinical development risk in exchange for milestone payments and royalties. Examples include the $400M, four-year Teva duvakitug agreement and the $700M Merck sac-TMT agreement supporting development through 2026.
• Co-Funding Agreements Joint financing arrangements under which BXLS co-funds clinical trials alongside a pharmaceutical partner. The first such partnership is with Johnson & Johnson to advance bleximenib (oral menin inhibitor for AML) across Phase 1, 2, and 3 studies as monotherapy and in combination.
• Life Sciences Term Loan and Credit Facilities Customized structured debt financing provided through Blackstone Life Sciences Advisors with Blackstone Credit & Insurance, including term loans, revolving credit facilities, and equity participation. Used by life sciences companies to refinance existing obligations and expand capital flexibility.
• Royalty Interest Investments Investments structured as royalty interests in approved or late-stage drug revenues, providing capital to pharma partners in exchange for a share of long-term product cash flows. Examples include BXLS's prior 1% royalty interest in Alnylam's AMVUTTRA and its 2020 $2B non-dilutive investment for a 50% royalty interest in LEQVIO.
• Company-Building / Ownership Strategy BXLS's ownership strategy of acquiring or building companies around deprioritized pharmaceutical assets. The flagship example is the build-out of Anthos Therapeutics around the abelacimab stroke-prevention therapy (originally deprioritized at Novartis), which Novartis later reacquired for up to $3.1B.

Quantifiable outcome

• 85-86% Phase III approval success rate for BXLS-backed assets vs ~48% industry average
• +4 more outcomes

Named customers6 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered flagship and core.

• Johnson & JohnsonflagshipStrategic or Co-development Partner · 22 February 2026Co-funding agreement with J&J to advance bleximenib (JNJ-75276617), an investigational oral menin inhibitor for acute myeloid leukemia (AML). Partners jointly finance Phase 1, 2, and 3 clinical trials as both monotherapy and in combination with AML-directed treatments for patients with KMT2A gene rearrangements or NPM1 mutations. Marked the first collaboration between the two organizations.
• Novartis AGcoreStrategic or Co-development Partner · 3 April 2025Novartis completed the acquisition of Anthos Therapeutics from Blackstone Life Sciences and Novo in a deal valued at up to $3.1 billion, with $925 million paid upfront. Anthos was built by BXLS around the Abelacimab stroke-prevention therapy, originally deprioritized at Novartis, before Novartis reacquired the company.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Royalty Pharma: Largest dedicated acquirer of biopharmaceutical royalty interests; directly comparable to BXLS's royalty monetization strategy (BXLS sold its AMVUTTRA royalty interest to Royalty Pharma for $310M). Both deploy capital against approved and late-stage drug cash flows.
• Bain Capital Life Sciences: Dedicated life sciences private equity franchise of Bain Capital; comparable to BXLS in deploying scale capital across biotech, pharma and medtech with both control buyouts and structured non-control investments.
• EQT Life Sciences: EQT's life sciences investment platform (formerly LSP); operates growth and venture capital funds across biotech and medtech, directly comparable to BXLS's mix of development-stage capital and company-building.
• Patient Square Capital: Healthcare-dedicated private equity firm focused on biopharma and medtech; similar model of large-scale non-control and control life sciences investments targeting development-stage assets and strategic deals.
• HealthCare Royalty Partners (HCRx): Specialist in structured financing and royalty/milestone monetization for biopharma; directly comparable to BXLS's royalty interest and strategic growth capital product lines.
• OrbiMed Advisors: Healthcare-dedicated investment firm across venture, growth, credit and royalty strategies; closely comparable to BXLS's multi-strategy life sciences platform, particularly its credit and structured financing capabilities.

Emerging players

• RA Capital Management: Crossover and private life sciences investor with structured financing capabilities across PIPE, royalty and private equity transactions; overlaps with BXLS's late-stage development capital focus.

Broad incumbents

• KKR Health Care Strategic Growth: Growth-oriented healthcare strategy within KKR; comparable to BXLS as a large, diversified alternative asset manager with a dedicated life sciences/healthcare investment platform.
• Carlyle Global Healthcare: Carlyle's global healthcare private equity franchise; comparable as a large incumbent PE platform deploying capital into pharma, biotech and healthcare services across stages.
• TPG Capital — Healthcare: TPG's healthcare investment platform spans pharma services, biopharma and medtech; comparable as a broad incumbent alternative asset manager with material life sciences exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/blackstone
• Facebookfacebook.com/blackstone
• LinkedInlinkedin.com/company/blackstonegroup
• Instagraminstagram.com/blackstone

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blackstone Life Sciences